Oral Bioavailability of Two Solid Formulations of GLPG0259.

Galapagos

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: GLPG0259 free base; Drug: GLPG0259 fumarate

Study type: Interventional

Funder types: Industry

Identifiers

NCT01322451

2010-022456-23 (EudraCT Number)

GLPG0259-CL-104

Details and patient eligibility

About

The purpose of the study is to evaluate the relative bioavailability of two solid oral formulations of GLPG0259 administered after a meal.

Enrollment: 12 patients

Sex: Male

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy male, age 18-50 years
• BMI between 18-30 kg/m², inclusive.

Exclusion criteria

• significantly abnormal platelet function or coagulopathy
• smoking
• drug or alcohol abuse

Trial design

12 participants in 2 patient groups

Single oral dose, single capsule

Experimental group

Treatment:

Drug: GLPG0259 free base

Single oral dose, two capsules

Experimental group

Treatment:

Drug: GLPG0259 fumarate